Aktis Oncology, Inc. AKTS
Set alert
14.59 USD -1.34 -8.41%
At close
14.71 +0.12 +0.83%
Pre-market · Nov 3, 6:32 AM ET
13.96 Day range 16.01
13.96 52-week range 34.19
- YTD
- -34.87%
- 1 year
- -34.87%
- Open
- 16.01
- Prev close
- 15.93
- Mkt cap
- 811.49M
- Vol
- 898.18K
- Avg vol
- 370.60K
- EPS
- -1.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.96
- High
- 16.01
- Forward P/E
- -8.45
- Beta
- 0.00
- Short ratio
- 10.89
- Inst. own
- 73.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 22.96
- 200-d avg
- 21.42
- 1y target
- 35.39
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.39 +142.6% upside
Now 14.59
- Target (low)
- 31.50
- Target (mean)
- 35.39
- Target (high)
- 40.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 10
- 2 months ago 9
- 3 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.45803 | -0.56 – -0.34 | 0.00 | 0.0% | 2.33M | 0.0% | 7 |
| Next quarter | -0.47987 | -0.61 – -0.12 | 0.00 | 0.0% | 2.13M | +13.8% | 7 |
| Current year | -1.69 | -1.95 – -1.27 | -78.34 | +97.9% | 10.25M | +57.7% | 8 |
| Next year | -2.15 | -3.02 – -1.08 | -1.69 | -27.4% | 9.67M | -5.7% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 9, 2026 | Oppenheimer | Initiated | — | Outperform |
| Aug 19, 2026 | Wedbush | Initiated | — | Outperform |
| Aug 19, 2026 | BMO Capital | Initiated | — | Outperform |
| Jul 14, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jun 16, 2026 | Raymond James | Initiated | — | Strong Buy |
| Jun 2, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 29, 2026 | William Blair | Initiated | — | Outperform |
| Mar 31, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 9, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Feb 3, 2026 | Leerink Partners | Initiated | — | Outperform |
| Feb 3, 2026 | JP Morgan | Initiated | — | Overweight |
| Jan 4, 2024 | Piper Sandler | Downgrade | Overweight | Neutral |
| Sep 7, 2023 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 7, 2023 | B. Riley Securities | Downgrade | Buy | Neutral |
| May 9, 2023 | Oppenheimer | Maintained | — | Outperform |
| May 9, 2023 | Roth MKM | Maintained | — | Buy |
| Jan 24, 2023 | B. Riley Securities | Initiated | — | Buy |
| Nov 15, 2022 | Oppenheimer | Maintained | — | Outperform |
| Sep 13, 2022 | Piper Sandler | Maintained | — | Overweight |
| May 3, 2022 | Piper Sandler | Maintained | — | Overweight |
| Nov 2, 2021 | Oppenheimer | Maintained | — | Outperform |
| May 4, 2021 | Roth Capital | Maintained | — | Buy |
| Jan 4, 2021 | Roth Capital | Maintained | — | Buy |
| Dec 20, 2019 | Northland Capital Markets | Maintained | — | Market Perform |
| Sep 18, 2019 | Northland Capital Markets | Downgrade | Outperform | Market Perform |
| Jul 10, 2019 | Northland Capital Markets | Upgrade | Market Perform | Outperform |
| Feb 5, 2019 | Northland Capital Markets | Downgrade | Outperform | Market Perform |
| Aug 30, 2018 | Oppenheimer | Initiated | — | Outperform |
| Jun 22, 2018 | Loop Capital | Initiated | — | Buy |